acipimox
Small moleculeexperimental
Acipimox is a niacin derivative used as a lipid-lowering agent. It reduces triglyceride levels and increases HDL cholesterol. It may have less marked adverse effects than niacin, although it is unclear whether the recommended dose is as effective as standard doses of niacin. — Wikipedia
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2019 (NCT03809793)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
HCAR2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAcipimox ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06229678 | Early Phase 1 (Phase 1) | Jan 25, 2024 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Texas, San Antonio |
| NCT03809793 | N/A | Feb 28, 2019 | Diabetes UK, Liverpool John Moores University, Royal Liverpool & Broadgreen University Hospitals NHS Truts, University of Liverpool |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Diabetes UK | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Liverpool John Moores University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2024 |
| Royal Liverpool & Broadgreen University Hospitals NHS Truts | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Liverpool | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 1 | 1 | 2024 |
6 organizations
Page 1 / 1